In the first model, CLL cells were stimulated with TLR9 agonist CpG and CD40L [34–36] followed by measurements of BrdU incorporation after an 8-day culture to assess cell proliferative capacity. The gene discussed is CD40LG; the disease is B-cell chronic lymphocytic leukemia.